乳腺癌组织LINC01503表达与术后复发转移的临床关系探讨-东南大学学报医学版

乳腺癌组织LINC01503表达与术后复发转移的临床关系探讨

单位：1. 郑州大学第一附属医院乳腺外科, 河南郑州 450052;
2. 郑州大学第五附属医院肿瘤内科, 河南郑州 450052

分类号：R737.9

出版年·卷·期（页码）：2025·44·第三期（378-386）

摘要：

目的: 探讨乳腺癌组织长基因间非编码核糖核酸(LINC)01503表达与术后复发转移的临床关系。方法: 选取2020年1月至2023年8月郑州大学第一附属医院392例乳腺癌患者,均行手术治疗。收集手术切除的癌组织及癌旁组织标本,采用实时荧光定量聚合酶链反应(RT-qPCR)法检测LINC01503相对表达量,比较不同临床病理特征乳腺癌患者癌组织LINC01503相对表达量。所有患者均持续随访至2024年3月或出现术后复发转移,根据随访结果分为复发转移组、无复发转移组。比较2组临床资料及癌组织LINC01503相对表达量,采用Cox回归法分析术后复发转移的影响因素,计算风险比(HR)及其95%置信区间(95%CI)。结果: 排除脱落病例后最终纳入384例;乳腺癌组织LINC01503相对表达量为3.35±0.72,高于癌旁组织的1.00(P＜0.05);原位癌患者癌组织LINC01503相对表达量低于其他病理类型患者(P＜0.05);三阴性型、肿瘤原发灶-淋巴结-远处转移(TNM)Ⅲ/Ⅳ期、肿瘤低/未分化、有脉管癌栓、有神经侵犯及有微卫星高度不稳定患者癌组织LINC01503相对表达量高于其他分子亚型、TNM Ⅰ/Ⅱ期、肿瘤中/高分化、无脉管癌栓、无神经侵犯及无微卫星高度不稳定患者(P＜0.05);随访5~49个月,中位数32(16,42)个月,术后复发转移率为18.49%(71/384);分子亚型三阴性型(HR=2.633,95%CI:1.607~4.314)、TNMⅢ/Ⅳ期(HR=2.892,95%CI:1.560~5.362)、肿瘤低/未分化(HR=3.165,95%CI:1.538~6.510)、脉管癌栓(HR=2.667,95%CI:1.660~4.286)、神经侵犯(HR=2.192,95%CI:1.505~3.194)、微卫星高度不稳定(HR=2.002,95%CI:1.420~2.821)、糖类抗原(CA)125(HR=2.121,95%CI:1.467~3.066)及癌组织LINC01503相对表达量(HR=3.083,95%CI:1.637~5.807)是术后复发转移的独立危险因素(P＜0.05)。结论: 乳腺癌患者癌组织中LINC01503相对表达量升高,不仅与病理类型、分子亚型、TNM分期、肿瘤分化程度、脉管癌栓、神经侵犯及微卫星高度不稳定有关,还是术后复发转移的危险因素。

Objective: To explore the clinical relationship between the expression of long intergenic non-coding ribonucleic acid(LINC) 01503 in breast cancer tissue and postoperative recurrence and metastasis. Methods: Three hundred and ninety-two patients with breast cancer in the First Affiliated Hospital of Zhengzhou University from January 2020 to August 2023 were selected for surgical treatment. Samples of surgically resected cancer tissues and adjacent tissues were collected, the relative expression of LINC01503 were detected by real-time fluorescence quantitative polymerase chain reaction(RT-qPCR). The relative expressions of LINC01503 in breast cancer tissues with different clinicopathological features were compared. All patients were followed up until March 2024 or postoperative recurrence and metastasis. According to the following up results, they were divided into recurrence and metastasis group and no recurrence and metastasis group. The clinical data and relative expression of LINC01503 in cancer tissues were compared between the 2 groups, the influencing factors of postoperative recurrence and metastasis were analyzed by Cox regression method, and the hazard ratio(HR) and 95% confidence interval(95%CI) were calculated. Results: Three hundred and eighty-four cases were included after the cases were excluded. The relative expression of LINC01503 in breast cancer tissues was 3.35±0.72, which was higher than that in paracancer tissues(1.00)(P<0.05). The relative expression of LINC01503 in cancer tissues of patients with carcinoma in situ was lower than that of other pathological type(P<0.05). The relative expression of LINC01503 in cancer tissues of patients with triple negative, tumor-node-metastasis(TNM) stage Ⅲ/Ⅳ, low/undifferentiated tumor, vascular cancer thrombus, nerve invasion and highly microsatellite instability were higher than those of other molecular subtypes, TNM stage Ⅰ/Ⅱ, medium/highly differentiated tumor, no vascular cancer thrombus, no nerve invasion and no highly microsatellite instability(P<0.05). The following up period was 5-49 months, median 32(16,42) months.The recurrence and metastasis rate was 18.49%(71/384).Molecular subtypes triple negative(HR=2.633, 95%CI:1.607-4.314), TNM stage Ⅲ/Ⅳ(HR=2.892, 95%CI:1.560-5.362), low/undifferentiated tumors(HR=3.165, 95%CI:1.538-6.510), vascular cancer thrombus(HR=2.667, 95%CI:1.660-4.286), nerve invasion(HR=2.192, 95%CI:1.505-3.194), highly microsatellite instability(HR=2.002, 95%CI:1.420-2.821), carbohydrate antigen(CA) 125(HR=2.121, 95%CI:1.467-3.066) and relative expression of LINC01503 in cancer tissues(HR=3.083, 95%CI:1.637-5.807) were independent risk factors for postoperative recurrence and metastasis(P<0.05). Conclusion: The relative expression of LINC01503 in cancer tissues of breast cancer patients is increased, and it is not only related to pathological type, molecular subtype, TNM stage, tumor differentiation degree, vascular cancer thrombus, nerve invasion and highly microsatellite instability, but also a risk factor for postoperative recurrence and metastasis.

参考文献：

[1] 孙雨露, 朱婷婷, 姚永忠.外周血炎症指标对乳腺癌预后评估作用的研究进展[J].东南大学学报(医学版), 2023, 42(6):960-964.
[2] DEO S S, SHARMA J, KUMAR S.GLOBOCAN 2020 report on global cancer burden:challenges and opportunities for surgical oncologists[J].Ann Surg Oncol, 2022, 29(11):6497-6500.
[3] RAJPUT S, SHARMA P K, MALVIYA R.Biomarkers and treatment strategies for breast cancer recurrence[J].Curr Drug Targets, 2023, 24(15):1209-1220.
[4] YAO Z T, YANG Y M, SUN M M, et al.New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer[J].Cancer Commun(Lond), 2022, 42(2):117-140.
[5] XIE J J, JIANG Y Y, JIANG Y, et al.Super-enhancer-driven long non-coding RNA LINC01503, regulated by TP63, is over-expressed and oncogenic in squamous cell carcinoma[J].Gastroenterology, 2018, 154(8):2137-2151.e1.
[6] FENG J, GAO F Y, LI Y Y, et al.Upregulation of LINC01503 promotes cervical cancer progression by targeting the miR-615-3p/CCND1 axis[J].J Cancer, 2021, 12(15):4552-4560.
[7] 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组.中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J].中国癌症杂志, 2023, 33(12):1092-1187.
[8] 叶骉飞, 王童非, 张双燕, 等.pT₁N₀M₀期乳腺癌患者术后10年后首次出现复发转移相关因素分析[J].陕西医学杂志, 2021, 50(11):1395-1399.
[9] QU F L, WU S Y, LI J J, et al.Ipsilateral breast tumor recurrence after breast-conserving surgery:insights into biology and treatment[J].Breast Cancer Res Treat, 2023, 202(2):215-220.
[10] 李梦晗.乳腺癌临床病理特征与术后复发转移相关因素的回顾性分析[D].呼和浩特:内蒙古医科大学, 2017.
[11] 李慧芳, 地力木拉提·艾斯木吐拉, 郭晨明, 等.乳腺癌改良根治术患者术后复发转移的危险因素及血清CA125、COX-2、sTNFR-P55的预测价值研究[J].现代生物医学进展, 2023, 23(2):384-389, 308.
[12] AHMADPOUR S T, ORRE C, BERTEVELLO P S, et al.Breast cancer chemoresistance:insights into the regulatory role of lncRNA[J].Int J Mol Sci, 2023, 24(21):15897.
[13] SHUAI Y, QIAN H, YUAN P.LINC01503 in cancer:from molecular mechanisms to therapeutic implications[J].Clin Exp Med, 2024, 24(1):120.
[14] 曹欢, 赵雷, 杨建旺, 等.LINC01503在喉鳞癌中表达增高并促进喉鳞癌进展[J].河北医学, 2024, 30(5):715-719.
[15] ZHANG M L, ZHAO T T, DU W W, et al.C-MYC-induced upregulation of LINC01503 promotes progression of non-small cell lung cancer[J].Eur Rev Med Pharmacol Sci, 2020, 24(21):11120-11127.
[16] 吕微, 王佳丽, 刘天旭, 等.LINC01503通过miR-342-3p/IGF2R轴促进上皮性卵巢癌的进展[J].中国肿瘤生物治疗杂志, 2023, 30(9):754-761.
[17] PENG X, GAO J, CAI C, et al.LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression[J].Biosci Rep, 2020, 40(6):BSR20193371.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录